Salix Pharmaceuticals, Ltd.'s MoviPrep(R) Granted FDA Marketing Approval; New Two-Liter Liquid Bowel Cleansing Prep For Colonoscopy

RALEIGH, N.C.--(BUSINESS WIRE)--Aug. 2, 2006--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for prescription MoviPrep(R) (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution). MoviPrep is indicated for bowel cleansing prior to colonoscopy. Salix licensed exclusive rights to MoviPrep in the United States from Norgine B.V., which has filed a patent application for the drug that, if granted, will provide protection until 2023. The Company's 2006 total product revenue guidance of $205 million remains unchanged at this time. We expect to launch MoviPrep during mid-fourth quarter 2006. The Company will consider changing 2006 total product revenue guidance upon the launch of MoviPrep.

Back to news